136 related articles for article (PubMed ID: 28338993)
21. Inhibition of interleukin-6 signaling with CNTO 328 enhances the activity of bortezomib in preclinical models of multiple myeloma.
Voorhees PM; Chen Q; Kuhn DJ; Small GW; Hunsucker SA; Strader JS; Corringham RE; Zaki MH; Nemeth JA; Orlowski RZ
Clin Cancer Res; 2007 Nov; 13(21):6469-78. PubMed ID: 17975159
[TBL] [Abstract][Full Text] [Related]
22. In the presence of bone marrow stromal cells human multiple myeloma cells become independent of the IL-6/gp130/STAT3 pathway.
Chatterjee M; Hönemann D; Lentzsch S; Bommert K; Sers C; Herrmann P; Mathas S; Dörken B; Bargou RC
Blood; 2002 Nov; 100(9):3311-8. PubMed ID: 12384432
[TBL] [Abstract][Full Text] [Related]
23. Formononetin-induced oxidative stress abrogates the activation of STAT3/5 signaling axis and suppresses the tumor growth in multiple myeloma preclinical model.
Kim C; Lee SG; Yang WM; Arfuso F; Um JY; Kumar AP; Bian J; Sethi G; Ahn KS
Cancer Lett; 2018 Sep; 431():123-141. PubMed ID: 29857127
[TBL] [Abstract][Full Text] [Related]
24. Janus activated kinase 2/signal transducer and activator of transcription 3 pathway mediates icariside II-induced apoptosis in U266 multiple myeloma cells.
Kim SH; Ahn KS; Jeong SJ; Kwon TR; Jung JH; Yun SM; Han I; Lee SG; Kim DK; Kang M; Chen CY; Lee JW; Kim SH
Eur J Pharmacol; 2011 Mar; 654(1):10-6. PubMed ID: 21172343
[TBL] [Abstract][Full Text] [Related]
25. Inhibition of JAK1/STAT3 signaling mediates compound K-induced apoptosis in human multiple myeloma U266 cells.
Park S; Lee HJ; Jeong SJ; Song HS; Kim M; Lee HJ; Lee EO; Kim DH; Ahn KS; Kim SH
Food Chem Toxicol; 2011 Jun; 49(6):1367-72. PubMed ID: 21420464
[TBL] [Abstract][Full Text] [Related]
26. Quinone methide tripterine, celastrol, induces apoptosis in human myeloma cells via NF-κB pathway.
Tozawa K; Sagawa M; Kizaki M
Int J Oncol; 2011 Nov; 39(5):1117-22. PubMed ID: 21850367
[TBL] [Abstract][Full Text] [Related]
27. Calmodulin antagonists induce cell cycle arrest and apoptosis in vitro and inhibit tumor growth in vivo in human multiple myeloma.
Yokokura S; Yurimoto S; Matsuoka A; Imataki O; Dobashi H; Bandoh S; Matsunaga T
BMC Cancer; 2014 Nov; 14():882. PubMed ID: 25424011
[TBL] [Abstract][Full Text] [Related]
28. Sorafenib inhibits endogenous and IL-6/S1P induced JAK2-STAT3 signaling in human neuroblastoma, associated with growth suppression and apoptosis.
Yang F; Jove V; Buettner R; Xin H; Wu J; Wang Y; Nam S; Xu Y; Ara T; DeClerck YA; Seeger R; Yu H; Jove R
Cancer Biol Ther; 2012 May; 13(7):534-41. PubMed ID: 22406995
[TBL] [Abstract][Full Text] [Related]
29. Cucurbitacin B exerts anti-cancer activities in human multiple myeloma cells in vitro and in vivo by modulating multiple cellular pathways.
Yang T; Liu J; Yang M; Huang N; Zhong Y; Zeng T; Wei R; Wu Z; Xiao C; Cao X; Li M; Li L; Han B; Yu X; Li H; Zou Q
Oncotarget; 2017 Jan; 8(4):5800-5813. PubMed ID: 27418139
[TBL] [Abstract][Full Text] [Related]
30. Azaspirane (N-N-diethyl-8,8-dipropyl-2-azaspiro [4.5] decane-2-propanamine) inhibits human multiple myeloma cell growth in the bone marrow milieu in vitro and in vivo.
Hamasaki M; Hideshima T; Tassone P; Neri P; Ishitsuka K; Yasui H; Shiraishi N; Raje N; Kumar S; Picker DH; Jacob GS; Richardson PG; Munshi NC; Anderson KC
Blood; 2005 Jun; 105(11):4470-6. PubMed ID: 15705788
[TBL] [Abstract][Full Text] [Related]
31. Different associations of CD45 isoforms with STAT3, PKC and ERK regulate IL-6-induced proliferation in myeloma.
Zheng X; Li AS; Zheng H; Zhao D; Guan D; Zou H
PLoS One; 2015; 10(3):e0119780. PubMed ID: 25781885
[TBL] [Abstract][Full Text] [Related]
32. Monensin-mediated growth inhibition in NCI-H929 myeloma cells via cell cycle arrest and apoptosis.
Park WH; Kim ES; Kim BK; Lee YY
Int J Oncol; 2003 Jul; 23(1):197-204. PubMed ID: 12792794
[TBL] [Abstract][Full Text] [Related]
33. 3-Formylchromone inhibits proliferation and induces apoptosis of multiple myeloma cells by abrogating STAT3 signaling through the induction of PIAS3.
Ko JH; Ho Baek S; Nam D; Chung WS; Lee SG; Lee J; Mo Yang W; Um JY; Seok Ahn K
Immunopharmacol Immunotoxicol; 2016 Oct; 38(5):334-43. PubMed ID: 27324722
[TBL] [Abstract][Full Text] [Related]
34. IL6 Promotes a STAT3-PRL3 Feedforward Loop via SHP2 Repression in Multiple Myeloma.
Chong PSY; Zhou J; Lim JSL; Hee YT; Chooi JY; Chung TH; Tan ZT; Zeng Q; Waller DD; Sebag M; Chng WJ
Cancer Res; 2019 Sep; 79(18):4679-4688. PubMed ID: 31337650
[TBL] [Abstract][Full Text] [Related]
35. Regulation of STAT3 and NF-κB activations by S-nitrosylation in multiple myeloma.
Kim J; Choi S; Saxena N; Singh AK; Singh I; Won JS
Free Radic Biol Med; 2017 May; 106():245-253. PubMed ID: 28232202
[TBL] [Abstract][Full Text] [Related]
36. Astragalus extract inhibits proliferation but enhances apoptosis in gastric cancer.
Wang Z; Dong L; Zhen Y; Wang Y; Qi D; Xu A; Meng X; Li W
Pak J Pharm Sci; 2016 Sep; 29(5):1473-1482. PubMed ID: 27731799
[TBL] [Abstract][Full Text] [Related]
37. 20(S)-25-methoxyl-dammarane-3β, 12β, 20-triol negatively regulates activation of STAT3 and ERK pathways and exhibits anti-cancer effects in HepG2 cells.
Ai HH; Zhou ZL; Sun LG; Yang MT; Li W; Yu CL; Song ZB; Huang YX; Wu Y; Liu L; Yang XG; Zhao YQ; Bao YL; Li YX
Apoptosis; 2017 Nov; 22(11):1404-1418. PubMed ID: 28864870
[TBL] [Abstract][Full Text] [Related]
38. Bazedoxifene exhibits growth suppressive activity by targeting interleukin-6/glycoprotein 130/signal transducer and activator of transcription 3 signaling in hepatocellular carcinoma.
Ma H; Yan D; Wang Y; Shi W; Liu T; Zhao C; Huo S; Duan J; Tao J; Zhai M; Luo P; Guo J; Tian L; Mageta L; Jou D; Zhang C; Li C; Lin J; Lv J; Li S; Lin L
Cancer Sci; 2019 Mar; 110(3):950-961. PubMed ID: 30648776
[TBL] [Abstract][Full Text] [Related]
39. BF211, a derivative of bufalin, enhances the cytocidal effects in multiple myeloma cells by inhibiting the IL-6/JAK2/STAT3 pathway.
Wu XY; Tian F; Su MH; Wu M; Huang Y; Hu LH; Jin L; Zhu XJ
Int Immunopharmacol; 2018 Nov; 64():24-32. PubMed ID: 30145467
[TBL] [Abstract][Full Text] [Related]
40. An activated JAK/STAT3 pathway and CD45 expression are associated with sensitivity to Hsp90 inhibitors in multiple myeloma.
Lin H; Kolosenko I; Björklund AC; Protsyuk D; Österborg A; Grandér D; Tamm KP
Exp Cell Res; 2013 Mar; 319(5):600-11. PubMed ID: 23246572
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
